Pharming Group (NASDAQ:PHAR - Get Free Report)'s stock price rose 5.7% during mid-day trading on Thursday . The company traded as high as $8.76 and last traded at $8.90. Approximately 1,935 shares were traded during mid-day trading, a decline of 60% from the average daily volume of 4,843 shares. The stock had previously closed at $8.42.
Analyst Ratings Changes
PHAR has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th. Oppenheimer reduced their target price on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a research report on Monday, October 28th. Finally, Jefferies Financial Group started coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a "buy" rating and a $14.00 price target on the stock.
View Our Latest Stock Report on Pharming Group
Pharming Group Stock Performance
The firm has a market capitalization of $588.12 million, a PE ratio of -33.25 and a beta of -0.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The company's fifty day simple moving average is $9.21 and its 200 day simple moving average is $8.43.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its position in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 47,997 shares of the company's stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 0.03% of the company's stock.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
